Anti-EGFRvIII chimeric antigen receptor transduced T-cell therapy - Kite Pharma
Alternative Names: Anti-EGFRvIII CARLatest Information Update: 11 Oct 2021
At a glance
- Originator Kite Pharma; National Cancer Institute (USA)
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Glioblastoma
Most Recent Events
- 03 Oct 2017 Kite Pharma has been acquired by Gilead Sciences
- 17 Sep 2015 Phase I/II development is ongoing in USA